Fuan Pharmaceutical (Group) Co., Ltd. (SHE:300194)
China flag China · Delayed Price · Currency is CNY
3.960
-0.050 (-1.25%)
May 20, 2026, 2:25 PM CST

SHE:300194 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Operating Revenue
1,6181,6782,3082,5712,3782,388
Other Revenue
60.1760.1783.176.9444.2264.71
1,6781,7382,3912,6482,4222,453
Revenue Growth (YoY)
-18.13%-27.31%-9.68%9.33%-1.28%3.58%
Cost of Revenue
1,0961,1311,1741,2811,066935.97
Gross Profit
582.44607.611,2181,3671,3551,517
Selling, General & Admin
385.78400.6804.891,0211,0921,217
Research & Development
130.42134.66153.22148.79142.89120.38
Other Operating Expenses
15.469.386.915.3116.2828.08
Operating Expenses
534.81550.92968.971,1821,2551,370
Operating Income
47.6256.69248.55184.51100.24147.59
Interest Expense
-24.17-22.15-23.34-29.57-26.94-20.45
Interest & Investment Income
154.26168.16106.8109.4190.0774.46
Currency Exchange Gain (Loss)
0.20.20.980.661.47-0.59
Other Non Operating Income (Expenses)
-2.78-5.97-4.69-0.85-1.4-1.76
EBT Excluding Unusual Items
175.14196.92328.3264.17163.44199.26
Impairment of Goodwill
-129.02-129.02--224.51-22.97-201.06
Gain (Loss) on Sale of Investments
-1.69-1.86-32.740.410.420.75
Gain (Loss) on Sale of Assets
0.150.270.01220.654.850.31
Asset Writedown
4.482.65-0.68-3.61-2.44-626.17
Other Unusual Items
20.6214.2817.333.2446.0734.93
Pretax Income
69.6783.24312.2290.36189.35-591.99
Income Tax Expense
7.26.7634.0355.95-11.4717.61
Earnings From Continuing Operations
62.4676.49278.17234.41200.82-609.59
Minority Interest in Earnings
0.40.511.67-2.543.79312.68
Net Income
62.8677279.84231.87204.61-296.91
Net Income to Common
62.8677279.84231.87204.61-296.91
Net Income Growth
-72.23%-72.48%20.69%13.32%--
Shares Outstanding (Basic)
1,2701,2831,1661,2201,2041,188
Shares Outstanding (Diluted)
1,2701,2831,1661,2201,2041,188
Shares Change (YoY)
10.70%10.06%-4.46%1.40%1.34%2.10%
EPS (Basic)
0.050.060.240.190.17-0.25
EPS (Diluted)
0.050.060.240.190.17-0.25
EPS Growth
-74.91%-75.00%26.32%11.77%--
Free Cash Flow
280.61203.8961.8113.3-43.6-155.91
Free Cash Flow Per Share
0.220.160.050.09-0.04-0.13
Dividend Per Share
0.0700.0700.0500.0500.050-
Dividend Growth
40.00%40.00%----
Gross Margin
34.71%34.96%50.91%51.63%55.97%61.85%
Operating Margin
2.84%3.26%10.39%6.97%4.14%6.02%
Profit Margin
3.75%4.43%11.70%8.76%8.45%-12.10%
Free Cash Flow Margin
16.72%11.73%2.58%4.28%-1.80%-6.35%
EBITDA
253.08260.54446.01392.88284.11321.89
EBITDA Margin
15.08%14.99%18.65%14.84%11.73%13.12%
D&A For EBITDA
205.46203.86197.45208.37183.87174.29
EBIT
47.6256.69248.55184.51100.24147.59
EBIT Margin
2.84%3.26%10.39%6.97%4.14%6.02%
Effective Tax Rate
10.34%8.12%10.90%19.27%--
Revenue as Reported
1,6781,7382,3912,6482,4222,453
Advertising Expenses
-18.8924.052.440.480.5
Source: S&P Global Market Intelligence. Standard template. Financial Sources.